Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating) were up 4.3% during mid-day trading on Wednesday . The stock traded as high as $3.18 and last traded at $3.17. Approximately 251,267 shares were traded during trading, a decline of 76% from the average daily volume of 1,031,935 shares. The stock had previously closed at $3.04.
Wall Street Analysts Forecast Growth
LYEL has been the subject of several research reports. HC Wainwright reduced their target price on Lyell Immunopharma from $12.00 to $11.00 in a report on Wednesday, November 9th. The Goldman Sachs Group downgraded Lyell Immunopharma from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $13.00 to $7.00 in a report on Friday, November 11th. Finally, Morgan Stanley cut their target price on shares of Lyell Immunopharma from $7.00 to $4.00 and set an “equal weight” rating on the stock in a report on Tuesday.
Lyell Immunopharma Trading Up 4.3 %
The company has a 50 day simple moving average of $3.53 and a 200 day simple moving average of $5.51. The stock has a market capitalization of $790.36 million, a PE ratio of -3.53 and a beta of -1.92.
Hedge Funds Weigh In On Lyell Immunopharma
A number of large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in Lyell Immunopharma in the second quarter worth $316,000. Amalgamated Bank acquired a new position in shares of Lyell Immunopharma during the 1st quarter worth $111,000. Camden Capital LLC purchased a new position in shares of Lyell Immunopharma in the 3rd quarter valued at about $110,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Lyell Immunopharma in the third quarter valued at about $114,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Lyell Immunopharma during the third quarter worth about $749,000. 45.04% of the stock is owned by hedge funds and other institutional investors.
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
- Get a free copy of the StockNews.com research report on Lyell Immunopharma (LYEL)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.